KLK3 and prostate carcinoma: In addition, immunoblot assays and quantitative analyses revealed that camptothecin (Cpt), a p53 inducer, induced p53 but inhibited MALT1 and PSA expression in p53 wild-type prostate carcinoma LNCaP cells dose dependently (Figure 2C).